Systemic therapies for salivary gland carcinoma (excluding adenoid cystic carcinoma): REFCOR recommendations by the formal consensus method.

Autor: Sarradin V; Département d'oncologie médicale, institut universitaire du cancer Toulouse - Oncopole, 1, avenue Irène-Joliot-Curie, 31100 Toulouse, France. Electronic address: sarradin.victor@iuct-oncopole.fr., Digue L; Département d'oncologie médicale, hôpital Saint-André, CHU de Bordeaux, Bordeaux, France., Vergez S; Département de chirurgie ORL et cervico-faciale, CHU de Toulouse-Larrey, université Toulouse III Paul-Sabatier, Toulouse, France; Département de chirurgie, institut universitaire du cancer Toulouse - Oncopole, Toulouse, France., Thariat J; Département de radiothérapie, centre François-Baclesse, Caen, France., Fakhry N; Département d'ORL et chirurgie cervico-faciale, hôpital La Conception, AP-HM, Marseille, France., Chabrillac E; Département de chirurgie, institut universitaire du cancer Toulouse - Oncopole, Toulouse, France., Bensadoun RJ; Centre de haute énergie, clinique Saint-Georges, Nice, France., Ferrand FR; Département d'oncologie médicale, institut Gustave-Roussy, Villejuif, France; Institut de recherche biomédicale des Armées, Brétigny-sur-Orge, France., Even C; Département d'oncologie médicale, institut Gustave-Roussy, Villejuif, France.
Jazyk: angličtina
Zdroj: European annals of otorhinolaryngology, head and neck diseases [Eur Ann Otorhinolaryngol Head Neck Dis] 2024 Sep; Vol. 141 (5), pp. 280-285. Date of Electronic Publication: 2023 Nov 30.
DOI: 10.1016/j.anorl.2023.11.004
Abstrakt: Objective: To determine the therapeutic indications for systemic medical treatment in the management of salivary gland carcinoma (excluding adenoid cystic carcinoma) according to the clinical situation.
Materials and Methods: The French Network of Rare Head and Neck Tumors (REFCOR) formed a steering group who drafted a narrative review of the literature published on Medline and proposed recommendations. The level of adherence to the recommendations was then assessed by a rating group, according to the formal consensus method.
Results: Salivary gland carcinoma is rare and there is currently insufficient evidence to indicate chemotherapy at the localized stage. At the metastatic stage, initial management can be based on a phase of monitoring for indolent disease. Some histological subtypes (salivary duct carcinoma and adenocarcinoma) are more aggressive and require systemic treatment from the outset. To guide systemic treatment, it is recommended to perform immunohistochemistry and molecular biology analyses (overexpression of HER2 and androgen receptors, NTRK fusion, next-generation sequencing).
Conclusion: Salivary gland carcinoma is a rare tumor for which there are currently few effective medical treatments. It is therefore recommended to include patients in clinical trials.
(Copyright © 2023 Elsevier Masson SAS. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: